Sarcopenia, traditionally associated with aging, is increasingly recognized in younger adults using GLP-1 receptor agonists for metabolic disease. This pilot study evaluated multimodal approaches—including ultrasound, CT, electrical impedance, microwave imaging, grip strength, and functional testing—to identify reliable, portable markers of muscle mass and quality. Patients with recent abdominal CT imaging and suspected sarcopenia underwent standardized assessments of the rectus femoris and brachioradialis. Preliminary results revealed several promising ultrasound-based and impedance-derived variables that correlated with CT-based muscle density and cross-sectional area. Additional microwave-based measurements also showed early signal. These findings demonstrate the feasibility of integrating low-cost bedside tools to detect early muscle deterioration in patients using GLP-1 agonists. Larger, powered studies with healthy controls are needed to refine diagnostic thresholds, validate inter-modality correlations, and establish practical clinical workflows for longitudinal sarcopenia surveillance.